Self Efficacy, Walking Ability, Gait Speed and Physical Activity in People With Chronic Lung Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Roberto P. Benzo, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01583595
First received: February 7, 2012
Last updated: April 1, 2013
Last verified: March 2013
  Purpose

Most patients with chronic lung disease underestimate their actual walking ability due to low confidence. To better understand the relationships between lung function, self-efficacy for walking (confidence in ability to walk a defined distance), actual walking ability for the same distance gait speed and physical activity level-PAL- (total energy expenditure/resting metabolic rate).

Quality of life, self efficacy for activity questionnaires, physical activity level measurement, 4-meter gait speed and 6-minute walk distance will be measured.


Condition
Chronic Lung Disease
Self-efficacy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Determining the Relationships Between Self-efficacy for Walking Ability, Gate Speed and Physical Activity in Patients With Chronic Lung Disease

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Analyze associations between self-efficacy for walking, gait speed, physical activity level and perceptions of symptoms in patient with chronic lung disease (COPD and Pulmonary Fibrosis) [ Time Frame: Day of enrollment. ] [ Designated as safety issue: No ]
    Correlation , regression models and mediation analysis (self efficacy and physical activity) will be performed.


Secondary Outcome Measures:
  • Predictive utility of 4-meter gait speed for estimating physical activity level (PAL) as validated by gold standard activity monitor. [ Time Frame: 1 week ] [ Designated as safety issue: No ]
    Measure 4-meter gait speed during standardized 6 mintute walk test and compare to armband activity monitor results to determine predictive ability, if any, on PAL in people with chronic lung disease.


Enrollment: 70
Study Start Date: December 2011
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adults with chronic lung disease

Criteria

Inclusion Criteria:

  • Men and women 40 years and older
  • Diagnosis of any chronic lung disease as evidenced by pulmonary function testing completed within the prior 12 months
  • Able to walk independently and successfully complete the 6-minute walk assessment

Exclusion Criteria:

  • Unable to walk without assistance or complete the 6-minute walk assessment
  • Patients unable to comprehend and accurately respond to the study questionnaires either by written or spoken communication
  • Patients diagnosed with or treated for a lower respiratory tract infection or COPD exacerbation within the prior 30 days
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01583595

Locations
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Roberto P Benzo, M.D., MSc Mayo Clinic
  More Information

No publications provided

Responsible Party: Roberto P. Benzo, Consultant Pulmonary and Critical Care Medicine, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01583595     History of Changes
Other Study ID Numbers: 11-008157
Study First Received: February 7, 2012
Last Updated: April 1, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Mayo Clinic:
Chronic Lung Disease
Exercise
Self-efficacy

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 17, 2014